Publications

Use of Micafungin as a Surrogate Marker to Predict Susceptibility and Resistance to Caspofungin among 3,747 Clinical Isolates of Candida using CLSI Methods and Interpretive Criteria, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Isavuconazole and Comparator Antifungals Tested against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

MALDI-TOF MS Identification of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Program, Lead author: Woosley LN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftaroline and Comparator Agents against 6,502 S. pneumoniae Isolates from United States Medical Centers over 5 Years (2008-2012), Lead author: Sader HS, presented at American Thoracic Society (ATS), May 17 – 22, 2013, Philadelphia, PA

Prevelance of &#223-lactamase-encoding Genes in Escherichia coli Strains Collected in the USA: Report of the SENTRY Antimicrobial Susceptibility Program, Lead author: Castanheira M, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Comprehensive Update of Dalbavancin Activity when Tested against Uncommonly Isolated Streptococci, Corynebacterium spp., Listeria monocytogenes and Micrococcus spp., Lead author: Jones RN, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Clonal expansion of Acinetobacter baumannii strains displaying elevated tigecycline minimum inhibitory concentration (MIC) values responsible for increasing resistance rates in Latin America (eposter), Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in European hospitals (2011) (oral), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme (oral), Lead author: Alm, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B, Lead author: Kassamali, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Characterisation of three new VIM enzymes, VIM-35, VIM-36 and VIM-37 identified in European countries: report of the SENTRY Antimicrobial Surveillance Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Beta-lactamase production among ceftazidime-resistant Pseudomonas aeruginosa from five European countries: high prevalence of oxacillinases and VIM enzymes in the SENTRY Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

AmpC and MexAB-OprM hyperexpression are most common mechanisms among ceftazidime- and imipenem-resistant Pseudomonas aeruginosa from Chinese hospitals, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Detection of plasmid-encoded CFR in clinical isolates of Enterococcus faecalis from Panamá City: report from the SENTRY Antimicrobial Surveillance Programme, Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Susceptibility rates in Latin American nations: report from the Emerging Markets Resistance Surveillance Programme, Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Resistance surveillance programme report for European nations (2011), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Longitudinal assessment of tigecycline activity tested against Gram-positive and Gram-negative organisms from European medical centres: results from the SENTRY Programme (2004-2012), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial susceptibility of Gram-negative bacteria causing urinary tract infections in European and United States hospitals (2009-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Screening for fluoroquinolone-resistance in staphylococcus aureus and Streptococcus spp using norfloxacin and EUCAST disc diffusion criteria, Lead author: Ahman, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Improved screen for beta-lactam-resistance in Streptococcus pneumoniae with the oxacillin 1-ug disk using the EUCAST disc diffusion method, Lead author: Matuschek, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Biapenem and biapenem/RPX7009 MIC quality control ranges using CLSI multi-laboratory M23-A3 study design, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo beta-lactamase-producing organisms, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline combined with avibactam tested against contemporary (2012) bacteria collected from USA patients with acute bacterial skin and skin structure infections, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010), Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Dalbavancin activity in the USA: reported from the SENTRY Programme (2012), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model, Lead author: Bhavnani, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Recent Resistance Surveillance Results from 12 Medical Centres Across China (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Molecular Characterization of Vancomycin-resistant Enterococcus Clinical Isolates Recovered from Hospitalized Patients in China, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Emerging Markets Resistance Surveillance Programme Report for 12 Asia-Pacific Nations (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Telavancin In Vitro Activity Against a Contemporary(2011–2012) Collection of Gram-positive Pathogens, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia

Activities of carbapenem and comparator agents against contemporary U.S. Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. by Morrow BJ, Pillar CM, Deane J, Sahm D, Lynch AS, Flamm RK, Peterson J and Davies TA. published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 412-416

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. by Vaara M, Sader HS, Rhomberg PR, Jones RN and Vaara T published in J. Antimicrob. Chemother. 2013; 68 (3): 636-639

Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in two global surveillance programs. by Castanheira M, Woosley LN, Diekema DJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 2013; 51 (1): 117-124

Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. by Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (2): 210-213

Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2013; 68 (4): 858-863

In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439

Update of dalbavancin spectrum and potency in the USA; Report from the SENTRY Antimicrobial Surveillance Program (2011). by Jones RN, Sader HS and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (3): 304-307

Surveillance of dalbavancin potency and spectrum in the United States (2012). by Jones RN, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 122-123

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88